Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Criteria for clinical diagnosis of antibody-mediated acute rejection (kidney)
- Antibody-mediated acute rejection
- Antibody-mediated rejection: C4d deposition
- Immunosuppressive drugs
- Immunologically non-specific drug therapy
- The risk of developing cancer after transplantation
- Current immunosuppressive drug therapy
- Defining the key objectives
- Is tolerance achievable in solid organ transplantation?
- Liver transplantation tolerance can be achieved in the clinic
- Hypotheses
- Liver transplant recipients – 20% IS free
- Microarray profiling can distinguish between tolerant and ID liver transplant recipients
- Kidney transplantation tolerance can be achieved in the clinic
- Indices of tolerance research network
- Diagnostic capabilities of combined biomarkers:
- Validation studies on independent cohorts from the ITN
- Inducing transplantation tolerance in the clinic
- Development of mixed chimerism strategies (1)
- Development of mixed chimerism strategies (2)
- HLA-mismatched renal transplantation
- Combined transplants from HLA single- haplotype mismatched living donors
- Full chimerism and tolerance without GvHD or engraftment syndrome
- Striving to minimise immunosuppression
- Phase 1/2a safety study
- ONE study trial(s)
- ONE study trial profile
- ONE study immunosuppression protocols: UK polyclonal Treg study
- Summary
Topics Covered
- Clinical diagnosis of antibody-mediated acute rejection
- Antibody-mediated rejection
- Current immunosuppressive drug therapy
- Minimising immunosuppressive therapy
- Transplantation tolerance
- Achieving transplantation tolerance in the clinic
- Inducing tolerance using chimerism
- HLA-mismatched renal transplantation
- The ONE study trial
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Wood, K. (2021, September 29). Factors influencing outcomes in clinical transplantation 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/UNAQ4144.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Emerita Kathryn Wood has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Factors influencing outcomes in clinical transplantation 2
Published on September 29, 2021
40 min
Other Talks in the Series: The Immune System - Key Concepts and Questions
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to the second part of this talk on clinical transplantation.
In the first part, I covered aspects that affect outcomes in clinical transplantation.
In the second part of the talk I'm going to be covering the approaches that are being taken to
minimise the side-effects of non-specific immunosuppression,
including the approaches that are being developed towards tolerance in clinical organ transplantation.
0:24
How do we diagnose antibody-mediated rejection in the kidney?
There are a number of studies now trying to refine the information that is
used by both the pathologists and the clinical teams, to diagnose antibody-mediated rejection.
This is constantly evolving through the Banff organisation, through both pathology and
as other markers including the presence of antibodies,
things are becoming more detectable before severe damage to the graft has been done.
To detect antibody-mediated damage to a transplanted kidney,
there is clinical evidence, because the graft starts to function poorly, and sometimes
goes into complete dysfunction; this can be monitored very well using biochemical parameters.
The presence of the antibodies in the circulating plasma of the patient can be detected now,
and at most centres patients will have blood taken on a regular basis,
to look for the presence of these antibodies which can potentially damage the graft.
If the graft is showing some degree of dysfunction, for kidneys the graft can be biopsied,
and that biopsy analysed by a skilled pathologist looking for signs of the rejection process.